Diagnostics

MicroGenDX Launches Its Patient-Focused Website to Streamline Access to Microbial Testing

Industry-Leading Clinical NGS Test Provider MicroGenDX Has Created a New Patient-Focused Website to Improve Access and Discovery of Its D2C…

7 months ago

Quest Supports Expansion of Community Center and Provides No-Cost Wellness Testing to Newark Faith Community

NORTHAMPTON, MA / ACCESSWIRE / May 2, 2024 / Quest Diagnostics: At a glance:Quest worked with St. James Health in…

7 months ago

Zomedica Strengthens Market Position with New Patents Issued for its TRUFORMA(R) Diagnostic Platform

Intellectual property portfolio now includes 188 Patents and 131 Trademarks providing robust protection for the Company's product platforms ANN ARBOR,…

7 months ago

Allarity Therapeutics’ Stenoparib Shows Clear Clinical Benefit and Achieves Significant Milestone with Early Conclusion of Phase 2 Trial in Advanced Ovarian Cancer

Boston (May 2, 2024)—Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ: ALLR), a clinical-stage pharmaceutical company dedicated to developing personalized…

7 months ago

EDAP to Announce First Quarter 2024 Financial Results on May 16, 2024

Company to host conference call and webcast on Thursday, May 16th at 8:30am EDT LYON, France, May 2, 2024 --…

7 months ago

LifeMD Becomes the First Virtual Primary Care Provider to Elevate GLP-1 Patient Care with Real-time, At-Home Monitoring of Blood Pressure and Body Composition

LifeMD and Withings Health Solutions partnership exemplifies the potential of digital health technology to transform virtual patient care and improve…

7 months ago

PROPHASE LABS INC. TO PRESENT FIRST QUARTER 2024 FINANCIAL RESULTS ON MAY 9

GARDEN CITY, NY, May 02, 2024 (GLOBE NEWSWIRE) -- ProPhase Labs Inc. (NASDAQ: PRPH), announced today that they will be…

7 months ago

Positive Initial Clinical Data Reported from Immutep’s Efti Combined with Radiotherapy and Checkpoint Inhibitor from Phase II Trial in Soft Tissue Sarcoma

Media Release Novel triple combination of efti with radiotherapy and anti-PD-1 therapy is well tolerated and has led to encouraging…

7 months ago

BioPorto A/S to Host First Quarter 2024 Earnings Webcast and Investor Meeting

May 2, 2024News release BioPorto A/S to Host First Quarter 2024 Earnings Webcast and Investor Meeting COPENHAGEN, DENMARK and BOSTON,…

7 months ago

CompuMed, FireStarter Collaborate to Further Shared Vision of Saving More Lives through Organ Donation and Transplantation

Companies aim to enhance organ donation efforts by pairing cutting-edge telediagnostic solutions with innovative marketing strategies LOS ANGELES, CA and…

7 months ago